MARKET

OVID

OVID

Ovid Therapeutics Inc
NASDAQ
2.280
+0.030
+1.33%
Opening 09:41 06/23 EDT
OPEN
2.200
PREV CLOSE
2.250
HIGH
2.306
LOW
2.190
VOLUME
57.56K
TURNOVER
--
52 WEEK HIGH
3.105
52 WEEK LOW
0.2851
MARKET CAP
425.54M
P/E (TTM)
-9.3673
1D
5D
1M
3M
1Y
5Y
1D
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy
Benzinga · 21h ago
Weekly Report: what happened at OVID last week (0615-0619)?
Weekly Report · 1d ago
Ovid Therapeutics director Anna Greka files initial beneficial ownership statement
PUBT · 5d ago
Weekly Report: what happened at OVID last week (0608-0612)?
Weekly Report · 06/15 09:24
Ovid Therapeutics Shareholders Back Board and Governance Proposals
TipRanks · 06/11 13:26
Ovid Therapeutics shareholders approve executive pay advisory proposal at annual meeting
PUBT · 06/11 13:03
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Ovid Therapeutics (OVID) and Establishment Labs Holdings (ESTA)
TipRanks · 06/08 17:30
Weekly Report: what happened at OVID last week (0601-0605)?
Weekly Report · 06/08 09:23
More
About OVID
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).

Webull offers Ovid Therapeutics Inc stock information, including NASDAQ: OVID real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OVID stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OVID stock methods without spending real money on the virtual paper trading platform.